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INTRODUCTION 
 
Thyroid has fascinated the surgeon for centuries; from the second 
millennium BC, when it has been recorded in Chinese literature. Ancient 
Chinese employed ground sheep’s thyroid for goitre and cretinism. 
Thyroid malignancy has been known to exist for over three centuries. In 
U.K its incidence is about 0.5 % of all cancers and is responsible for 
fewer than 0.5 % of all deaths due to cancer. Nevertheless it has attracted 
the attention of surgeon, for a number of reasons.  
 
1. Varying biological behaviour of  various types thyroid 
malignancy   
 
2. There is a diagnostic challenge arising out of various modes 
of presentation  
 
3. Technical interest for a precise surgical approach 
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Even now, there is no general agreement regarding the treatment of 
thyroid cancer. Long history together with evolving mode of treatment 
has made it extremely difficult to judge the effectiveness of any single or 
combined therapeutic approach where in widely different view points 
have been expressed with great amount of convictions on either side. 
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AIM OF THE STUDY 
 
These are the reasons which prompted us to undertake a study of 
this kind. In our institution hemithyroidectomy is being done for thyroid 
swellings based on preoperative clinical aid, biochemical evaluation 
including FNAC study.   
 
The aim of the study is 
 
1. To analyse the histopathological examination of 
hemithyroidectomy specimen for malignancy in whom the 
hemithyroidectomy was done for suspected benign lesions. 
 
2.  Management of those Hemithyroidectomized patients 
with proved malignancy, with various modalities of 
treatment such as completion thyroidectomy, TSH 
suppression with eltroxine, Radioiodine ablation, or 
chemotherapy. 
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In must be stated at the outset that in a good number of patient’s 
prolonged follow up has not been done, as this study covers a group of 
patients seen in recent past nor it covers any cases treated with 
radioisotopes. 
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SURGICAL ANATOMY OF THYROID GLAND 
 
          Normal thyroid gland weighs about 20 – 25 gms. It has two lateral 
lobes connected by an isthmus in the midline. The lateral lobes extend 
along the side of the larynx from the middle of thyroid cartilage above to 
the sixth tracheal ring below. Lateral lobes measures approximately 5 x 3 
cm (slightly larger in women). They reside in a bed between the trachea 
and larynx medially and two carotid sheaths and sternocleidomastoid 
muscles laterally. 
 
          A strong condensation of vascular connective tissue known as 
suspensory ligament of Berry, binds the gland firmly to each side of the 
cricoid cartilage and it is the ligament together with the pretracheal fascia, 
which splits to invest the gland, which makes the thyroid move up and 
down on swallowing. 
 
          Anteriorly, the thyroid lobes are in relation to the strap muscles. 
Situated on the posterior surface of the lateral lobes of the gland are the 
parathyroid glands and recurrent laryngeal nerves, which lie in 
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Tracheoesophageal groove just medial to lateral lobes. The pyramidal 
lobe of Lolouette of variable size is a long, narrow projection of thyroid 
tissue extending upward from the isthmus lying on the surface of the 
thyroid cartilage usually to the left of the prominence of that structure. It 
represents a vestige of embryonic thyroglossal duct and can be 
demonstrated in about 80% of patients at operation. 
 
           The capsule of the thyroid gland (surgical capsule) sends fibrous 
septa into the gland substance, dividing into numerous lobules. Each 
lobule consists of 30 to 40 follicles that contain colloid. These are the 
main secretary and storage elements. 
 
DEVELOPMENT OF THYROID  
 
 The thyroid gland is developed from median bud of the pharynx 
(the thyroglossal duct) which passes from the foramen caecum at the base 
of the tongue to the isthmus of the thyroid. 
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 Ultimobranchial body which arises from a diverticulum’s of the 
fourth pharyngeal pouch of each side amalgamates with the corresponding 
lateral lobe. Para follicular “c” cells are derived from the neural crest and 
reach the thyroid via the ultimobranchial body. Recently consideration has 
been given to the possibility that some “c” cells are of endodermal rather 
than neural crest origin. 
 
BLOOD SUPPLY  
 The arterial supply is rich and extensive anastomosis occur between 
the main thyroid arteries and branches of tracheal and oesophageal 
arteries. The main supply is via two paired arteries. A third vessel 
occasionally supplies the lower pole of one or other side.  
 
 The superior thyroid artery, the first branch from the anterior aspect 
of external carotid, after giving off its sternocleidomastoid and superior 
laryngeal branches pierces the pre-tracheal fascia as a single vessel to 
reach the summit of the upper lobe. The external laryngeal nerve is 
immediately behind the artery as the vessel approaches the upper pole. In 
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thyroidectomies, the artery is ligated right at the pole, to avoid damage to 
the nerve. 
 
 The artery divides on the gland into an anterior branch that runs 
down to the isthmus and a posterior branch that runs down to the back of 
the lobe and anastamoses with anterior ascending branch of the inferior 
thyroid artery from the lower pole. A separate branch from the left artery 
may supply the pyramidal lobe. 
 
 The inferior thyroid artery is generally much larger than the 
superior thyroid artery but it is less constant, being absent or duplicated 
on one side or other in 10% of individuals. It arises from the thyrocervical 
trunk and passes upward for a variable distance before looping down 
running medially behind the carotid sheath to reach the posterolateral 
aspect of the gland at the junction of middle and lower thirds. 
 
 The suspensory ligament always contains small branches. The 
recurrent laryngeal nerve has a variable relationship to the artery but 
always lies behind the pretracheal fascia. If this structure remains intact 
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during thyroidectomy, the nerve will not have been divided. It is close 
behind the fascia. However may be bruised or caught in a ligature; hence 
the preference of some but not all surgeons ligating the inferior thyroid 
artery well lateral to the gland before it begins to divide into its terminal 
branches. 
 
 Numerous unnamed accessory arteries arise from the oesophagus 
and trachea, but the most frequently encountered is the thyroidea ima 
(Neubauers’ Artery) which enters the lower part of the isthmus in 3% of 
individuals. It springs from the brachiocephalic trunk, right common 
carotid artery or direct from the arch of aorta and represents a persistent 
embryonic vessel that usually disappears. In the absence of inferior 
thyroid artery on one side, Thyroidea ima artery may be the principal 
source of blood supply to the lobe and therefore substantial. 
 
 Venous plexus forms under the capsule. The named thyroid veins 
although three in number like the arteries are subject to greater variation. 
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 The superior thyroid vein, formed by a confluence of vessels from 
the upper pole crosses the common carotid artery high in the neck to drain 
into the internal jugular vein, which overlies the inferior thyroid artery, 
also ends in the internal jugular vein after crossing the common carotid 
artery. 
 
 The internal jugular or brachiocephalic vein in the anterior 
mediastinum and are intimately associated with the thyrothymic 
ligaments, which expand inferiorly as the lobes of thymus.     
 
INNERVATION 
 
 The bulk of sympathetic (vasoconstrictors) supply is derived from 
the middle cervical ganglion and enters the gland on the inferior thyroid 
artery. Some fibres from the superior cervical ganglion travel with the 
superior thyroid artery. The parasympathetic fibres are derived from the 
vagus and reach the gland via branches of laryngeal nerves. 
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LYMPHATIC DRAINAGE  
 
 The thyroid is generously supplied with lymphatics and a rich 
network ramifies throughout the gland. They drain primarily into the 
mediastinal nodes inferiorly, tracheo- oesophageal nodes laterally and the 
midline delphian nodes superiorly. 
 
 From the lower pole they pass with the inferior thyroid artery back 
to its origin from the subclavian behind the carotid sheath into the postero 
inferior group. 
 
IMPORTANT ANATOMICAL RELATIONSHIPS 
 
 Vagus nerve having entered the mediastinum gives off the recurrent 
nerves, which return to the neck having circled around the arch of aorta on 
the left and the right subclavian artery on the right. 
 
It ascends in the tracheo-esophageal groove and has variable 
relationship with the inferior thyroid artery on each side. Occasionally, the 
nerve divides itself early and branches around the artery in 10% of 
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individuals. In approximately, 0.25% of individuals the recurrent 
laryngeal nerve on the right is non-recurrent but passed directly from the 
vagus to cricothyroid muscles.  
 
As it takes the same course as the inferior thyroid artery, it is 
particularly vulnerable if its presence is unrecognised when this vessel is 
routinely ligated laterally. The recurrent laryngeal nerve innervates the 
intrinsic muscles of the larynyx except for the cricothyroid muscle. 
Damage to this nerve leads to vocal cord paralysis on the same side.  
 
Riddell indicated that among cases in which surgeons”avoid “rather 
than expose the recurrent laryngeal nerve there is incidence of vocal cord 
damage. It is very important for the surgeon to carefully identify this 
nerve at the time of operation.  
 
SUPERIOR LARYNGEAL NERVE 
 
This also arises from the vagus (inferior ganglion) and divides at 
the level of hyoid bone into a large internal laryngeal nerve and a small 
external laryngeal nerve. The latter runs close to the superior thyroid 
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artery but at a deeper plane. Immediately above the superior pole of 
thyroid, it terminates as the nerve supply to the cricothyroid muscle which 
acts as tensor of vocal cords on the same side. 
 
THE CERVICAL SYMPATHETIC CHAIN 
 
This underlies the carotid sheath just medial to the vagus on the 
pre-tracheal fascia and is in close proximity to the inferior thyroid artery 
as it arches around medially.  
 
PARATHYROID GLANDS 
 
There are normally four parathyroid glands, the upper pair of which 
lies in close proximity to the dorsal aspect of thyroid. They are usually 
found above and medial to where recurrent laryngeal nerve crosses the 
inferior thyroid artery, frequently tacked round behind its branches. The 
lower parathyroid gland on each side is situated within a 2 cm radius of 
the lower pole of thyroid typically on its surface anterolaterally and at a 
level below and medial to where the recurrent laryngeal nerve crosses the 
inferior thyroid artery.  
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PHYSIOLOGY  
 
The thyroid, largest endocrine gland in the body produces three 
hormones. Thyroxine (T4), tri-iodo thyronine (T3) and calcitonin. T4&T3 
are both stored in the colloid consisting primarily of thyroglobulin which 
is an iodinated glycoprotein. Thyroglobulin stores are dependent on 
adequate dietary iodine intake, which is essential for T3 & T4 synthesis. 
 
Iodine is derived mainly from milk and diary products with a 
smaller proportion from salt, water and fish and iodised salt. Plasma 
levels of iodine vary widely, depending on geographical locality. Iodides 
are absorbed in the stomach and the upper gastrointestinal tract 
approximately two-thirds is excreted via kidneys and one-third is trapped 
in the thyroid where 90% of body stores of iodine are found. 
 
The steps in the synthesis of thyroid hormone are:  
 
1. Concentration of iodine in the gland. 
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2. Rapid oxidation of iodides to iodine by a peroxidase 
enzyme system. 
3. The formation of precursor  amino acids: 3-mono-
iodothyronine (MIT) and 3-5 Di-iodothyronine (DIT)  and 
 
4. The coupling of these inactive iodothyronines to form 
the hormonally active iodothyronines & Tri-iodothyronine and 
Thyroxine (T4). When iodine transport is defective, because of 
either pharmacologic inhibitors or spontaneous disease, goiter 
and or hypothyroidism result. 
 
The hormonally active T4 & T3 & iodothyronines are held in 
peptide linkage with a specific protein, thyroglobulin which forms the 
major component of intra follicular colloid. 
 
Release of active hormone into circulation involves hydrolysis of 
the throglobulin by proteases and peptidases resulting in T4 & T3. The 
activity of these enzymes is enhanced by administration of TSH. 
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Thyroid stimulating hormone produced by thyrotrophic cells of 
anterior pituitary control the complex enzymatic reactions that trap iodine, 
convert it into T4 & T3 and release it into the circulation. When T3 & T4 
raises above the normal range, TSH production is shut down by a negative 
bio-feed back loop. 
 
 Release of TSH is regulated by Thyrotrophin releasing Hormone 
(TRH) which is produced in the hypothalamus. TRH enters the capillary 
bed of the stalk median eminence, passing via portal veins and sinusoids 
to bathe the anterior pituitary cells. TSH biosynthesis shows a circadian 
rhythm, its secretion will be maximum in the evening before the onset of 
sleep, remaining high overnight and falling to a low around mid-day. 
 
The role of calcitonin in normal physiology has not been 
established in men, but it may be involved in the regulation of plasma 
calcium and phosphate metabolism. However, thyroidectomy which 
removes all Para follicular “c” cells causes no disturbances of calcium 
homeostasis. 
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The rise in plasma calcitonin which occurs during pregnancy and 
lactation appears to have no effect on maternal skeleton but calcium 
resorption may be prevented by a concomitant increase in the level of 
circulating cholecalciferol. 
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SURGICAL PATHOLOGY 
 
CLASSIFICATION OF THYROID MALIGNANCY 
 
PRIMARY 
 
 Follicular epithelium – differentiated  
 
• Follicular 17% 
• Papillary 60% 
 
Follicular epithelium undifferentiated 
 
• Anaplastic 13% 
Lymphoid cells 
• Lymphoma 4% 
Para follicular 
• Medullary 6% 
SECONDARY 
• Metastatic 
• Local infiltration 
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DEGROOT’S CLINICOPATHOLOGICAL STAGING: 
 
Stage 1     -    Tumors with single or multiple intrathyroidal foci. 
 
Stage ll    -     Tumors with cervical metastases that are not fixed and  are  
 without invasion. 
 
Stage lll   -     Tumors with fixed cervical metastases or tumors with  local  
cervical invasion beyond the thyroid capsule. 
 
Stage lV  -     Metastases outside the neck. 
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TNM staging of thyroid malignancy (AJCC 2002) 
T0 - No evidence of Primary tumor 
T1 - Tumor 2 cm or less in greatest dimension limited to thyroid  
T2 - Tumor >2cm but not more than 4 cm in greatest dimension  
  limited to thyroid  
T3 - Tumor > 4 cm limited to thyroid or with minimal extra  
  thyroidal extension  
T4 a  - Any tumor extending beyond thyroid capsule to invade  
  subcutaneous soft tissues, larynx, trachea, oesophagus, RLN  
T4b - Tumor invades prevertebral fascia or encases carotid artery  
  or mediastinal vessels  
N0 - No palpable lymph nodes 
N1 - Regional nodal metastases 
  N1a - Level VI ( Pretracheal, paratracheal &  
  prelaryngeal / Delphian nodes 
  N1b - Unilateral, bilateral or Contralateral cervical or   
  mediastinal nodes 
M0 - No distant metastases 
M1 - Distant metastases 
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Differentiated thyroid cancer risk group definitions (From Lahey 
Clinic Foundation) 
Low Risk Group 
 
A  All younger patients without distant metastases (men < 41 ; 
women < 51 years) 
B  All older patients with : 
 1. Intra thyroidal papillary cancer or follicular cancer with minor 
capsular involvement 
 2. Primary cancers < 5 cm in diameter 
 3. No distant metastases 
  
High Risk Group 
A  All  patients with distant metastases  
B  All older patients with : 
 1. Extra thyroidal papillary cancer or follicular cancer with major 
tumor capsular involvement and 
 2. Primary cancers < 5 cm in diameter or larger regardless of extent 
of disease 
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PAPILLARY CARCINOMA 
 
  This is the most common type of thyroid cancer, which runs 
a slow clinical course. Peak incidence occurs in 3rd to 4th decade. Female 
to male ratio is 3:1. Most commonly presents as thyroid swelling. 
 
  Histological subtyping by Hawk and Hazard 
 
1. Pure papillary 
 
2. Mixed papillary and follicular 
 
3. Follicular variant of papillary 
 
4. Tall cell variant 
 
The cancers are often multicentric within thyroid gland. 33 to 40% 
cases exhibit microscopic or gross tumor involvement within contra 
lateral lobe. 
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Macroscopically tumor is grayish white, poorly defined nodule of 
varying size with areas of hemorrhagic necrosis, cyst formation with 
occasionally visible papillae. 
 
Microscopically there appears neoplastic epithelium on fibro 
vascular stalks often projecting into cystic spaces. Epithelium is usually 
single layer and cubical with homogenous cytoplasm, surrounding ovoid 
nucleus with fine chromatin and optically clear appearance often called 
“ORPHAN ANNIE NUCLEI”. Laminated calcified spherules called 
“PSAMMOMA BODIES” are present in 40%. 
 
10 year survival rate is 84%. However with extra thyroidal spread it 
falls to 50%. 
 
MINIMAL PAPILLARY CARCINOMA  
 
Lesions less than 1cm without local invasion or lymph node 
metastasis, often found as an incidental finding in thyroidectomy 
specimen operated for another benign lesion 
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OCCULTPAPILLARY CARCINOMA   
 
Primary lesion less then 1.5cm which are often impalpable. 
FOLLICULAR CARCINOMA 
 
Incidence is 10 to 18%. It tends to occur in old age with peak 
incidence in fifth decade. They often present as single, solid expansile 
tumor mostly unencapsulated. Multifocality and lymphatic spread is 
uncommon. Metastasis by blood stream is common.  
 
Macroscopically they appear unencapsulated and invasive nature is 
apparent only histologically. Microscopically various sized follicles and 
trabecular cords of cuboidal neoplastic cells with compact hyperchromatic 
nuclei and mitosis. Capsular and vascular invasion are prominent features. 
 
The tumor and its metastases are most part functional in that they 
take up radioiodine, which gives an important therapeutic option. 
Prognosis depends on the extent of invasion and distant metastases. In 
their absence, 10-year survival rate is 72% but in their presence, it is only 
44%. 
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HURTHLE CELL TUMOUR 
 
This is considered as a variant of follicular neoplasm. 
Microscopically the cells are arranged in sheets with eosinophilic 
cytoplasm (Askanazy cells). In electron microscopy, cytoplasm is packed 
with mitochondria. 
 
Incidence of carcinoma in Hurthle cell tumor varies between 5.32 
to 62% in different clinical series. Histologically benign lesions however 
latter metastasized in 2.5 to 11.5% of patients. The cells are less likely to 
concentrate radio iodine.  
 
MEDULLARY CARCINOMA 
 
It is a C-cell calcitonin producing tumor of thyroid. 80% case are 
sporadic and 20% are associated with multiple endocrine neoplasia II, 
which occurs in family with autosomal dominant trait. Familial cases are 
often multifocal and bilateral. 
 
Calcitonin secreted by the tumor cells is used as a tumor marker. 
Carcinoembryonic antigen is also elevated in most of the patients.  
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Patients are usually presented with thyroid nodule associated with 
cervical lymphadenopathy in 20% and symptoms like dysphagia, diarrhea 
may be a prominent feature and episodic flushing may also occur which 
are all due to serotonin, prostaglandin E2, F2 alpha secreted by the tumor. 
The tumor shows no sex predilection.  
 
Macroscopically tumor appears as firm grayish, finely calcified 
mass. Microscopically nests of closely packed polygonal cell with 
eosinophilic granular cytoplasm and hyper chromatic nuclei, set in fibrous 
stroma that stains for amyloid and may show calcium deposits.     
The tumor tends to have protracted course. Dissemination occurs 
by lymphatics as well as by blood stream. Overall 10 year survival rate is 
57%. 
 
ANAPLASTIC CARCINOMA 
 
 It commonly occurs in 7th to 8th decade. Its incidence is higher in 
endemic goitre area. It has been proved that many of these tumors arise 
from pre existing differentiated thyroid malignancy as a result of the 
original tumor is undiagnosed or inadequately treated. Clinically it 
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presents with rapidly enlarging thyroid swelling usually with respiratory 
distress. 
  
 Macroscopically tumor is firm and white with areas of necrosis, 
replacing thyroid and extending into adjacent structures. 
 
  Microscopically three types are recognized. 
 
1. Spindle cell variant with cells in bundles or whorls 
resembling sarcoma with numerous mitoses. 
 
2. Small cell variant consisting of round cells with hyper 
chromatic nuclei and scanty cytoplasm. 
 
3. Giant cell variant with spindle cells and bizarre 
pleomorphic giant cells with frequent atypical mitoses. 
Prognosis is poor. Over all 5 year survival is 10 – 15%. 
75% patients die with 1 year. 
 
LYMPHOMA 
 
 It occurs frequently in middle to old aged women, presenting with 
rapidly enlarging painless mass in thyroid. It is due to NHL in all patients. 
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Coexistent Hashimoto’s thyroidits occurs in most patients. It has been 
suggested that chronic antigenic stimulation of lymphocytes causes 
transformation into lymphoma cells. 
 
Over all 5 year survival is 86% if the lesion is confined to thyroid 
but falls to 38% with extra thyroidal diseases. 
 
METASTATIC CARCINOMA 
 
 It is present in 2 – 4 % of patients dying of malignant disease. 
Bronchogenic carcinoma accounts for 20% thyroid secondary deposits. At 
autopsy 3% of all Bronchogenic carcinoma demonstrates thyroid 
metastasis. The other common tumours metastasizing to thyroid are from 
breast, lung, kidney or malignant melanoma. 
 
 Clinically they may appear similar to primary thyroid cancer but 
microscopically they differ. Direct extension from adjacent carcinoma 
may involve thyroid. This type of malignancy is associated with poor 
prognosis.  
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NATURAL HISTORY AND PATHOGENESIS 
Development of thyroid tumor is intimately associated with 
 
1. Iodine deficiency 
 
2. TSH stimulation 
 
The process of oncogenesis conceived to be a series of events 
introduced by genetic and environmental factors which alter growth 
control. 
 
Van middlesworth (1988) pointed out that iodine deficiency may 
increase the invasiveness of thyroid cancer through TSH stimulation. 
 
As pointed out by Sarda A.K et al., (Brit. J. Surg. Nov. 1986). 
The TSH levels in patients presenting with solitary nodular thyroid 
carcinoma was significantly higher than the benign solitary nodule. The 
mean TSH level of non – solitary thyroid nodular carcinoma was in high 
normal range.  
 
Also shown by Bubenhofer and Holdinger (Br. J. Surg. 
Nov.1986) that on reexamining all their patients with thyroid cancer from 
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Zurich (1924 – 1974), they found a relative reduction of anaplastic cancer 
after iodine prophylaxis. 
 
Some of the following factors can affect the natural progress of disease. 
 
1. ROLE OF RADIATION 
 
It is now generally recognized that external beam radiotherapy to 
treat benign and malignant conditions of head and neck can bring both 
benign and malignant nodular changes in thyroid. It has been 
demonstrated that there is a straight line increase in incidence up to a dose 
of about 1500 rads, but only after a mean latency of 25 years or more. 
Refetoff et al . , found that 25% had palpable abnormally of thyroid and 
6.8% of total group have thyroid cancer. 
 
Papillary carcinoma is the usual type associated with radiation 
exposure. It is now shown that high dose radiation (i.e) > 2000 rads also 
increases the prevalence of thyroid cancer, which was once thought to be 
of no risk to thyroid. 
 
 36
The risk of exposure from radioisotope study of thyroid has also 
been implicated. Now in many hospitals 1123 or 99m Tc instead of 1 131 is 
being used as a preventive action, since thyroid exposure is greatly 
diminished. 
 
2. GOITRE 
 
In a good number of patients with carcinoma of thyroid there is a 
preexisting goitre was present for a long time. In Fosters series incidence 
of malignancy in patients operated for non toxic goitre was about 10%. 
 
A good number of patients operated for non toxic single nodular 
goitre have turned to be malignant. The proportion of such adenomas 
turning malignant had been 15.8% in Ward series, 24.5 % in Crile series, 
24.4% in Cole series, and 25% in Shaw series (Tata Memorial). In Our 
study, this is about 16.7%. 
 
The association of papillary carcinoma with Hashimoto’s 
thyroiditis was observed in Mayoclinic and it appears to be protective 
against development of postoperative tumor recurrence. 
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3. HORMONAL FACTORS 
 
The striking preponderance of thyroid cancer in females raises the 
possibility of female sex hormones as an etiological factor. In one study, 
an independent and increasing risk was observed with increasing total 
number of pregnancy. In another series women who had a history of 
breast cancer were almost three times more likely to develop thyroid 
cancer. More recent study show that late menarche and late age at first 
pregnancy predisposing to increased risk for developing thyroid cancer. 
However, the mechanism remains obscure.   
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MATERIALS AND METHOD 
 
Our study covers the result of analysis of 72 patients who 
underwent hemithyroidectomy based on preoperative investigations which 
suggested benign lesions, but the histopathological examination proved to 
be malignant. The period of study was 2½ years from May 2005 to 
October 2007 in our institution. The criteria for patient selection were  
 
1. Clinically solitary nodule of thyroid 
 
2. No suspicious lymphnode enlargement 
 
3. Clinically Euthyroid 
 
4. Clinically no adjacent structure invasion or any distant 
metastasis 
5. FNAC of thyroid showed follicular neoplasm or 
benign lesions 
 
6. Otherwise, general condition is fit for surgery 
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All the 72 patients underwent Hemithyroidectomy and biopsy 
reports were taken for our study, and the patients were subsequently 
followed up. 
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CLINICAL STUDY 
AGE AND SEX INCIDENCE 
 
In our study, the minimum age was 19 years and the maximum was 
60 years. Male to female ratio was 1:8.9. 
 
Age group
In years 
Female Male Total 
< 20 7 1 8 
21 – 30 16 1 17 
31 – 40 20 0 20 
41 – 50 15 4 19 
>51 7 1 8 
Total 65 7 72 
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INVESTIGATIONS 
 
Apart from routine blood investigations, the following specific 
investigations were done. 
 
1. Ultra sonogram of the thyroid gland. 
 
2. Thyroid hormonal profile including total T4, T3 and 
TSH level. 
 
3. Fine needle aspiration cytology of the thyroid 
swelling.  
 
FNAC study of the thyroid swelling was done and the 
interpretations were as follows. 
 
 Number Percentage (%) 
Follicular neoplasm 20 27.8 
Non Neoplastic 
Goitre 
52 72.2 
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All the 72 patients underwent hemithyroidectomy, our pathologist 
did histopathological examination of the specimen, and the interpretations 
were as follows: 
 Number Percentage (%) 
Follicular Adenoma 48 66.7 
Papillary Carcinoma 9 12.5 
Follicular Carcinoma 3 4.2 
Adenomatous Goiter 4 5.5 
Hashimoto’s Thyroiditis 4 5.5 
Lymphocytic Thyroiditis 1 1.4 
Follicular Adenoma with 
Papillary Hyperplasia 
1 1.4 
Follicular Adenoma with 
Lymphocytic Thyroiditis 
1 1.4 
Total 72 100.0 
 
The number of patients who presented with malignancy in their 
hemithyroidectomy specimen was 12. The incidence was 16.7% 
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 Number Percentage (%) 
Papillary Carcinoma 9 12.5 
Follicular Carcinoma 3 4.2 
Total 12 16.7 
 
The ratio of papillary to follicular carcinoma in our study was 3:1. 
 
 
 Sex related incidence of malignancy in hemithyroidectomized 
patients as follows: 
 
 Male Female 
Papillary Carcinoma 1 8 
Follicular Carcinoma 0 3 
 
Age related incidence as follows: 
Age Group Number 
<20 1 
21 - 30 5 
31 – 40 4 
41 – 50 0 
>50 2 
 
The malignancy is common in third and fourth decades in our study. 
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MANAGEMENT 
 
After diagnosing malignancy in hemithyroidectomized patients, 
further treatment was planned based on risk factors as well as patients 
willingness. 
 
Our patients were managed by 
  
1. Completion Thyroidectomy followed by suppressive dose of 
thyroxin 
 
2. Suppressive dose of thyroxine alone for TSH suppression 
 
1. COMPLETION THYROIDECTOMY FOLLOWED BY 
SUPPRESSIVE DOSE OF THYROXINE 
 
This was done in four patients  
1. One male patient with papillary carcinoma 
 
2. Two female patient with papillary carcinoma 
 
3. One female patient with follicular carcinoma 
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METHOD OF COMPLETION THYROIDECTOMY 
 
By excising the old scar skin flaps were raised. Strap muscles 
which were adherent with thyroid capsule, carefully released and after 
ligating vascular pedicle, completion thyroidectomy was done. Every 
effort was made to safeguard both parathyroids as well as recurrent 
laryngeal nerve. The wound was closed with vacuum drainage. 
 
II. SUPPRESSIVE DOSE OF THYROXINE ALONE FOR TSH 
SUPPRESSION  
 
It was offered to remaining 8 patients who were not willing for re- 
operation the dose was 0.3mg per day and the patients were subjected 
regular follow up after explaining the risk of malignancy.                     
 
III. RADIO IODINE THERAPY  
 
It was not given to any patients because of non availability. 
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IV. EXTERNAL RADIOTHERAPY & CHEMOTHERAPY 
 
No external radio therapy and chemotherapy was given. 
The completion thyroidectomy specimens were subjected to 
histopathological examination and the results were as follows. 
Papillary Carcinoma 1 
Follicular Carcinoma 0 
No evident of Malignancy 2 
Well encapsulated follicular adenoma 1 
 
 
POST OPERATIVE FOLLOW-UP   
 
After surgery, the patients resumed normal diet on the next day of 
surgery. Antibiotics were exhibited for 5 – 7 days. Drains removed after 
24 – 48 hours. Sutures were removed on 6 – 7 days. Patients were back to 
home on 8th day with advise to attend regular follow up. No morbidity 
was reported after hemithyroidectomy. 
 
After completion thyroidectomy, out of four patients, we had 
transient hypocalcaemia in one patient and another patient with transient 
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vocal cord plasy. Later both patients recovered completely with 
conservative treatment. No permanent hypocalcaemia or permanent vocal 
cord plasy was noticed in our patients. After completion thyroidectomy 
the patients were put on suppressive dose of thyroxin 0.3mg per day and 
advised for regular follow-up. 
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PROGNOSIS AND FOLLOW-UP 
 
The average period of follow-up in our study was 4 – 24 months. 
During follow-up, through clinical examination was done to detect the 
recurrence or metastasis in the cervical nodes. So far no one of our 
patients developed any complication like local recurrence or nodal 
metastasis. 
 
The dose of thyroxin therapy was adjusted to keep the serum TSH 
level undetectable or less than 0.1 to 0.3 mU/L. none of them have so far 
developed any toxic symptoms. All the patients were doing well so far. 
Follow-up with 1131   scan or with serial estimation of thyroglobulin assay 
was not done because of the non-availability.  
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DISCUSSION 
 
 We reviewed the world literature and references for our study. The 
incidence of malignancy in hemithyroidectomized patients as revealed in 
world literature is as follows. 
 
Authors Incidence In % 
Fredrich et al., 24.3 
Adwok et al., 15.0 
Crile et al., 24.5 
Ward et al., 15.8 
Cole et al., 24.4 
Gharib et al., 25.0 
Aschraft et al., 16.0 
DH Shaw (Tata Memorial) 25.0 
Our study 16.7 
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Incidence of malignancy in solitary nodule of thyroid for which the 
hemithyroidectomy was done ranges from 11 – 20% (Kendall & Condon 
1969, Pasarras et al, 1972). The reported incidence where solitary nodule 
goitre turning into malignancy was already discussed. 
 
In a study by C.F.J. RUSSEL (UK) who performed 
hemithyroidectomy for solitary nodule of thyroid, the incidence of 
malignancy among those 61 patients was about 13%. 
 
In the world literature, accuracy of FNAC is 70 – 97%. Although 
FNAC provides useful information regarding nature of thyroid swelling 
the reported incidence of false negative reports is significant and is about 
17% (CUSI K. et al., 1990). Therefore, it is clear that a negative report 
for malignancy from FNAC study should be cautiously interpretated. If 
thyroid cancers are not be missed a liberal policy of surgical resection of 
thyroid should be done preferably a hemithyroidectomy. More over 
FNAC cannot differentiate follicular adenoma from follicular carcinoma. 
 
 51
Some authors’ experience with FNAC and final pathological 
diagnosis is discussed below. 
 
Authors FNAC  
(Benign and 
Indeterminate) 
Histopathologically 
malignant 
Percentage 
(%) 
Altavilla et al., 
1990  
213 26 12.2 
Hamming et al., 
1990 
133 9 6.8 
Caplan et al., 
1991 
127 34 26.8 
Layfield et al., 
1991 
90 22 24.4 
La. Rosa et al., 
1991 
622 68 10.9 
Klemi et al., 
1991 
174 10 5.7 
Wax M.K. et al., 
1992 
244 32 13.0 
Piromalli et al., 
1992 
138 23 16.7 
Our study 2007 72 12 16.7 
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It has been recommended that incidental papillary cancer detected 
following surgery for benign thyroid disease confined within the capsule 
of the thyroid are indolent tumors with little if any clinical significance. 
The completion thyroidectomy is not advised for all cases they may be put 
on suppressive dose of thyroxine and closely observed (Surgical Clinical 
of North America, June 1995). 
 
But it has been proved that the residual malignant focus is found in 
contra lateral lobe in 50% patients with papillary carcinoma and in 33% 
with follicular carcinoma. Incidence of recurrence in opposite lobe is 7 – 
10%, so completion total thyroidectomy is justified in patients who have 
thyroid carcinoma 1cm or greater. (Endocrinology and metabolism 
clinics of North America, march 1996). 
 
Completion thyroidectomy was done in four of our patients, in 
whom three patients with papillary carcinoma and one patient with 
follicular carcinoma because the size of the tumor was 4cm and above 
preoperatively. 
 
 53
Further more completion thyroidectomy facilitates 1131 scan to be 
done at later time for detections of metastasis because presence of normal 
thyroid tissue competes with metastases for radio iodine obtained. 
 
We referred the world literature for completion thyroidectomy. An 
analysis of the derived references was discussed below: 
 
 Wax M.K. et 
al., 
University of 
virginia (1992) 
Miccoli P. 
et al., 
Italy 
(1998) 
S.K.Mishra et 
al.,  
SGPGIMS, 
Lucknow 1989 
- 97 
Our 
study 
2005 -
2007 
No. of completion 
thyroidectomy 
32 19.0 22.0 4 
Residual Foci (%) 2 15.8 55.0 25 
Transient 
Hypocalcaemia (%) 
15 0 18.2 25 
Transient RLN 
Palsy (%) 
3 0 9.1 25 
Permanent 
Hypoparathyroidism 
(%) 
3 0 0 0 
Permanent RLN 
Palsy (%) 
0 0 0 0 
Mortality (%) 0 0 0 0 
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It is evident from the above studies that completion thyroidectomy 
can be done safely with minimal morbidity and no mortality  Rao et al 
and Levin et al  showed that in their study completion thyriodectomy are 
safe with low mortality. 
 
RADIOIODINE ABLATION 
 
None of our patients were treated with radio iodine. The dose of 
1131 required for ablation of contra lateral lobe is high which carries risk 
of leukaemia and lymphoma (De Groot L.J et al). Bandeson et at, reported 
a series of 10 parathyroid adenoma that developed in patients who 
received 1131 ablation .Because of these reasons 1131 ablation is not much 
useful in treating remaining thyroid tissue.   
 
It has been recommended and proved that in low risk patients the 
type of surgery does not affect the survival adversely. 
 
Wolff H.et al (1979-1988) reported 5 years survival rate for 
differentiated thyroid cancer was from 81.5% to 100% in stage T1N0M0 
(microcarcinoma) for the patients who underwent less radical procedures 
like hemithroidectomy (Zentral bl-Chir 1989;114(18):1202-8).  
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In another study at university of Rome by Russo et al(1997). 
Among 16 patients with microcarcinoma, 8 underwent total 
thyroidectomy and another 8 underwent hemithyroidectomy, and 
observed that there was no difference in long term results between 
different surgical treatment for microcarcinoma of thyroid. (Minerva 
Chir, 1997 July-August 52(7-8) 891-900). 
 
Brooks et al., treated 222 patients with differentiated thyroid 
carcinoma with total thyroidectomy (43 patients) or less than total 
thyroidectomy (179 patients) and found no differences in recurrence or 
survival rate. They believe that patients with occult papillary thyroid 
carcinoma or follicular carcinoma with minimal capsular invasion can be 
treated with thyroid lobectomy and isthumectomy, because the prognosis 
after such treatment approaches 100%. 
 
Woolner et al agree that treatment of choice for occult papillary 
carcinoma is Hemithyroidectomy and isthumectomy followed by TSH 
suppression. Because, inspite of multicentricity is high, there is extremely 
low incidence of clinical carcinoma in opposite lobe after 
hemithyroidectomy and TSH suppression. 
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CONCLUSION 
 
Based on our study certain conclusion is arriving at incidence of 
malignancy in Hemithyroidectomized patients are 16.7% which correlates 
with world literature (15%-25%).  
 
FNAC results showing benign lesions should be cautiously 
interpreted because of significant false negative reports. Conclusive 
reports can not be obtained by FNAC in follicular carcinoma. 
 
Most of the incidentally discovered malignancies following 
Hemithyroidectomies are papillary type (papillary to follicular ratio is 
3:1) 
 
Most of these tumours can be regarded as occult and minimal 
because they rarely show evidence of extrathyroidal spread in papillary 
carcinoma or major capsular invasion in follicular carcinoma. These 
tumours mostly follow a benign course even with the risk of recurrence in 
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the contralateral lobe. Completion thyroidectomy offers effective 
treatment in a group of selected patient’s with minimal morbidity.   
 
In low risk patients supplementary dose of thyroxin for TSH 
suppression offers equally efficient therapeutic option. 
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PROFORMA 
 
INCIDENCE OF MALIGNANCY IN HEMITHYROIDECTOMIZED 
PATIENTS 
 
Name   :   Case No  : 
Area of Residence :   I.P.No.   : 
   :   Age/Sex  : 
      Ward   : 
Occupation  :     
 
CLINICAL PRESENTATION 
 
Duration  :   Past History  : 
Side   :   Personal History : 
Pain   :   H/o irradiation  : 
Dysphagia  :   Toxic Symptoms  : 
Voice Change  :   
Family History : 
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CLINICAL EXAMINATION 
 
Side    :    Pressure Signs  : 
Size    :       Nodal Status   : 
Position  :   Spine and Cranium  : 
Consistency  :   Cardiovascular System: 
Fixity   :   Respiratory System  : 
Carotids   :   Abdomen  : 
Eyes    :   Others    : 
FNAC   : 
Diagnosis  : 
 
INVESTIGATIONS 
 
HB%   :   X-ray neck   : 
TC   :   X-ray chest  : 
DC   :   ECG   : 
ESR   :   BP   : 
Urine : ALB  :   USG NECK   : 
 : SUG     ENT opinion  : 
Blood Urea  :   Blood Group  : 
Blood Sugar  :   Rh Typing   : 
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T3    :   FNAC   : 
T4    :   TSH   : 
Others    :  
   
Medical endocrinology opinion 
 
MANAGEMENT 
 
Hemithyroidectomy  :   Biopsy   : 
Completion  
Thyroidectomy  :   Biopsy   : 
Thyroxin Alone   : 
Complications  : 
 
FOLLOW UP 
 
Hormonal Therapy   : 
Radio Iodine   : 
Chemotherapy   : 
Radiotherapy   :   
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FNAC STUDY
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ANATOMY – RELATIONSHIP OF THYROID GLAND  
 
 
 
 
 
 
 
 
 
 
 
 
 
 74
 
 
 
 
 
 
 
 
 
 
 
NORMAL THYROID FNAC 
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PAPILLARY CARCINOMA - THYROID 
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FOLLICULAR CARCINOMA - THYROID 
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HYPOTHALAMO – PITUITARY – THYROID AXIS  
 
 
 
 
 
 
 
 
 
 
 
 
 
FOLLICULAR VARIANT OF 
 PAPILLARY CARCINOMA 
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PAPILLARY CARCINOMA WITH NUCLEAR 
CROWDING AND NUCLEAR GROOVING  
 
 80
HURTHLE CELL CARCINOMA 
 
 
 
 
 
 
THYROID LYMPHOMA 
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A CASE OF SOLITARY NODULE RIGHT LOBE OF 
THYROID  
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